Application and Multi-Stage Optimization of Daylight Polymer 3D Printing of Personalized Medicine Products.
DoE
additive manufacturing
mebeverine hydrochloride
personalized drugs
photopolymerization
solid dosage forms
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
12 Apr 2022
12 Apr 2022
Historique:
received:
11
03
2022
revised:
06
04
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Additive technologies have undoubtedly become one of the most intensively developing manufacturing methods in recent years. Among the numerous applications, the interest in 3D printing also includes its application in pharmacy for production of small batches of personalized drugs. For this reason, we conducted multi-stage pre-formulation studies to optimize the process of manufacturing solid dosage forms by photopolymerization with visible light. Based on tests planned and executed according to the design of the experiment (DoE), we selected the optimal quantitative composition of photocurable resin made of PEG 400, PEGDA MW 575, water, and riboflavin, a non-toxic photoinitiator. In subsequent stages, we adjusted the printer set-up and process parameters. Moreover, we assessed the influence of the co-initiators ascorbic acid or triethanolamine on the resin's polymerization process. Next, based on an optimized formulation, we printed and analyzed drug-loaded tablets containing mebeverine hydrochloride, characterized by a gradual release of active pharmaceutical ingredient (API), reaching 80% after 6 h. We proved the possibility of reusing the drug-loaded resin that was not hardened during printing and determined the linear correlation between the volume of the designed tablets and the amount of API, confirming the possibility of printing personalized modified-release tablets.
Identifiants
pubmed: 35456677
pii: pharmaceutics14040843
doi: 10.3390/pharmaceutics14040843
pmc: PMC9029863
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : 2018/31/B/ST8/01327
Références
Molecules. 2020 Dec 29;26(1):
pubmed: 33383691
Adv Exp Med Biol. 2008;624:117-24
pubmed: 18348452
Int J Pharm. 2020 Oct 15;588:119732
pubmed: 32768528
AAPS PharmSciTech. 2018 Nov;19(8):3355-3361
pubmed: 29948979
Biomaterials. 2016 Feb;80:121-133
pubmed: 26708089
Pharmaceutics. 2019 Oct 18;11(10):
pubmed: 31635414
J Pharm Sci. 2017 Jul;106(7):1697-1705
pubmed: 28347731
Bioact Mater. 2020 Jan 22;5(1):110-115
pubmed: 32021945
J Pharm Sci. 2020 Oct;109(10):2943-2957
pubmed: 32679215
Pharmaceutics. 2019 Dec 03;11(12):
pubmed: 31816898
Eur J Pharm Sci. 2019 Jul 1;135:60-67
pubmed: 31108205
Pharmaceutics. 2019 Jun 11;11(6):
pubmed: 31212649
Eur J Pharm Biopharm. 2020 Apr;149:58-76
pubmed: 31982577
Int J Pharm. 2017 Oct 30;532(1):313-317
pubmed: 28888978
Int J Pharm. 2016 Apr 30;503(1-2):207-12
pubmed: 26976500
Drug Dev Ind Pharm. 2020 Sep;46(9):1385-1401
pubmed: 32715832
J Control Release. 2016 Jul 28;234:41-8
pubmed: 27189134
Molecules. 2019 Dec 04;24(24):
pubmed: 31817060
Biomed Pharmacother. 2020 Nov;131:110644
pubmed: 32853908
Int J Pharm. 2020 Jun 30;584:119428
pubmed: 32445906
Pharm Res. 2018 Jul 11;35(9):176
pubmed: 29998405
Pharmaceutics. 2021 Apr 25;13(5):
pubmed: 33922928
Pharmaceutics. 2019 Dec 07;11(12):
pubmed: 31817900
Eur J Pharm Sci. 2021 Mar 1;158:105688
pubmed: 33359483